Evidence map›Paper›PMID 37264655›Full record

ReviewRecent patents on nanotechnology2024

Recent Advancements in Novel Formulations of Anti-psoriatic Agents for Effective Delivery: Clinical Importance and Patent Survey.

Nikhil Dadwal, Balak Das Kurmi, Dilpreet Singh, Amrinder Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nikhil DadwalDepartment of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India.
Balak Das KurmiDepartment of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India.
Dilpreet SinghDepartment of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India.
Amrinder SinghDepartment of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India.
Indo Soviet Friendship College of Pharmacy · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn autoimmune-mediated dermatological ailment featuring recurrent episodes is acknowledged as psoriasis. Around the world, 2-3% of people suffer from this autoimmune skin condition.

objectivesThe primary goal of the current review is to analyse and determine the effectiveness of conventional and emerging nano technological strategies to alleviate psoriasis and discuss future perspectives.

methodsA thorough search of numerous electronic databases, including Science Direct, Scopus, Google Scholar, Clinical Trials, Google Patents, Research Gate, and PubMed, yielded all the data used in this review paper about the management of psoriasis

resultsNano technological approaches are gaining prominence since they enable targeted delivery, rapid onset of action with limited systemic exposure. Researchers have investigated innovative, alternative therapeutic approaches that are both secure and efficient for treating psoriatic conditions. Further, the potential role of numerous psoriatic conventional therapies has been explored. The patents granted or in process to address psoriasis

conclusionRelying on the extensive literature review, it can be inferred that nanoparticles based novel delivery strategies have the possibility of enhancing the pharmacological activity and eliminating or resolving problems associated with this ailment. The different drug delivery systems available for the treatment of psoriasis along with the clinical trials in different stages, patents in process and granted, the commercialized status of therapeutic molecules, and the future of research in this area have been thoroughly reviewed.

Indexed as

Drug Delivery SystemsPatents as TopicPsoriasisClinical RelevanceDermatologic AgentsHumansLiposomesNanotechnologyDermatologic AgentsLiposomesbiologicscytokinesnanocarrier.patentsPsoriasistopical

Identifiers

PMID37264655
OpenAlexW4379093367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.